Pharmaceuticals

111 to Announce Second Quarter 2019 Unaudited Financial Results on August 15, 2019

SHANGHAI, Aug. 1, 2019 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform inChina , today announced that it will report its unaudited financial results for the second quarter endedJune 30, 2019, before U.S. markets open o...

2019-08-01 20:00 5811

Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal

INCHEON, South Korea, July 31, 2019 /PRNewswire/ -- Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals. UCB's anti-tau candi...

2019-07-31 19:00 921

GC Pharma Reports Q2 2019 Results

YONGIN, South Korea, July 30, 2019 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months endedJune 30, 2019. Key Figures Q2 2019(1) Growth(1) Total revenues KRW 35...

2019-07-30 22:31 6949

Alvotech and Cipla Gulf Enter Into a Partnership for the Commercialization of Key Biosimilar in Select Emerging Markets

REYKJAVIK, Iceland and MUMBAI, India, July 29, 2019 /PRNewswire/ -- Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC ("Cipla Gulf"), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087) (NSE: CIPLA EQ; hereafter referred to as "Cipla"), today ...

2019-07-29 12:00 4210

China Biologic Products to Report Second Quarter 2019 Financial Results

BEIJING, July 26, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2019 financial resu...

2019-07-27 04:30 9499

NanoCellect Biomedical Expands Distribution to Australia and New Zealand

Company enters exclusive agreement with Millennium Science Pty Ltd SAN DIEGO, California, July 24, 2019 /PRNewswire/ -- NanoCellect Biomedical Inc., a leader in the development and manufacture of microfluidic cell sorting solutions for cell-based assays, today announced an exclusive agreement wit...

2019-07-24 21:57 920

111 Signs Strategic Cooperation with Harbin Pharmaceutical Group

SHANGHAI, July 24, 2019 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, today announced the signing of a strategic cooperation agreement with Harbin Pharmaceutical Group Holding Co., Ltd. (HPGC, SHSE: 600664), which has...

2019-07-24 20:00 7372

CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML

SUZHOU, China, July 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced today that it has received approval from China National Medical Products Administration (NMPA) to initiate a Phase I bridging registrational study of ivosidenib (TIBSOVO) for the treatment of rela...

2019-07-22 12:17 6500

Yuyu Pharma Receives Recognition for Outstanding Company Culture in Korea

SEOUL, South Korea, July 17, 2019 /PRNewswire/ -- Yuyu Pharma has received recognition as a Great Place to Work from the mayor of Jechoen city. The company also supported a recent HeForShe movement sponsored by the city of Jechoen. HeforShe is an UN-led gender equality movement that focuses on th...

2019-07-17 21:00 1657

Yuyu Pharma held the campaign for enhancing corporate transparency

SEOUL, South Korea, July 10, 2019 /PRNewswire/ -- Yuyu Pharma, a Korean pharmaceutical company celebrated its third year of implementing Yuyu's compliance management system by inviting senior management to its "Self-Compliance Day" workshop.

2019-07-11 16:43 1650

MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China

ROCKVILLE, Md. and SHANGHAI, July 10, 2019 /PRNewswire/ -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and I-Mab Biopharma (I-Mab), aChina and U.S....

2019-07-11 04:01 1699

CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST

SUZHOU, China, July 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient has been dosed inChina with avapritinib in the ongoing global Phase III VOYAGER clinical trial. This study is designed to evaluate the safety and efficacy of avapritini...

2019-07-10 10:23 6795

Medeon Led and Completed Investments in Panther Orthopedics and Prodeon

TAIPEI, , July 8, 2019 /PRNewswire/ -- Medeon Biodesign, Inc. (TPEx: 6499), aTaiwan publicly traded medical device company, is pleased to announce that it recently led and closed two investments, in Panther Orthopedics and Prodeon. Panther Orthopedics is a Silicon Valley startup company pioneerin...

2019-07-08 17:10 12738

CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019

Novel real world evidence for AFSTYLA® and IDELVION® to be highlighted MELBOURNE, Australia, July 1, 2019 /PRNewswire/ -- Global biotherapeutics leaderCSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation factor programs at this ...

2019-07-02 06:15 7213

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

GAITHERSBURG, Md., June 25, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces onJune 24, 2019, that the first patient has been dosed in a ...

2019-06-25 22:01 1150

Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies

SHANGHAI and NEW YORK, June 24, 2019 /PRNewswire/ -- Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capitalize on the rapid internationalization of clinical trials between the US andChina while maintain...

2019-06-25 04:00 1166

Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist

OSAKA, Japan, June 24, 2019 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi" or "the Company") announces that the Company has concluded an agreement with Eddingpharm (hereafter "Eddingpharm") to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name inJapan: MULPLETA® ...

2019-06-24 22:00 1266

China Jo-Jo Drugstores Enters into Strategic Cooperation Framework Agreement with Zhejiang Medical Insurance Bureau

HANGZHOU, China, June 24, 2019 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a healthcare provider inChina, announced today that...

2019-06-24 20:30 6464

CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA

SHANGHAI, June 19, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for the trea...

2019-06-19 18:00 2581

Reistone Announces First Patient Dosed in Two Phase II Global Studies of SHR0302 JAK Inhibitor for Ulcerative Colitis and Crohn's Disease

SHANGHAI, June 14, 2019 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone) announced today dosing of the first patient in their Phase II global clinical trials (RSJ10101 and RSJ10201) of SHR0302 in patients with Ulcerative Colitis and Crohn's disease respectively. The Phase II studies ...

2019-06-14 20:30 1426
1234567 ... 40